Diabetes area participation analysis: a review of companies and targets described in the 2008 – 2010 patent literature

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.20, Iss.12, 2010-12, pp. : 1627-1651

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel glucokinase activators: a patent review (2008 – 2010)

By Sarabu Ramakanth Berthel Steven J Kester Robert F Tilley Jefferson W

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 1, 2011-01 ,pp. : 13-33

Informa Healthcare

Access to resources Recommend Favorite

MEK inhibitors: a patent review 2008 –– 2010

By Trujillo John I

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 7, 2011-07 ,pp. : 1045-1069

Informa Healthcare

Access to resources Recommend Favorite

Bradykinin receptor antagonists – a review of the patent literature 2005 – 2008

By Fincham Christopher I Bressan Alessandro Paris Marielle Rossi Cristina Fattori Daniela

Expert Opinion on Therapeutic Patents, Vol. 19, Iss. 7, 2009-07 ,pp. : 919-941

Informa Healthcare

Access to resources Recommend Favorite

BACE2 as a new diabetes target: a patent review (2010 – 2012)

By Southan Christopher

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 5, 2013-05 ,pp. : 649-663

Informa Healthcare

Access to resources Recommend Favorite

Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 – 2013

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 24, Iss. 5, 2014-05 ,pp. : 573-595

Informa Healthcare

Access to resources Recommend Favorite